glp 1 suicide Reassuring' findings suggest GLP-1 receptor agonists do not increase risk Unpacking the Data on GLP-1

As demand for GLP-1 weight loss injections grows, primary care teams may need stronger counselling, safety-netting and review processes

Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial

183 Conversely, weight reduction achieved with GLP-1s can improve symptoms of obstructive sleep apnea, a common obesity-related condition

[DOI] [PMC free article] [PubMed] [Google Scholar] 4.Mojsov S., et al

Whilst the US Food and Drug Administration (FDA) has approved five drug therapies to treat obesity (orlistat, phentermine/topiramate, lorcaserin, naltrexone/bupropion, liraglutide), the European Medicines Agency (EMA) has approved only three drug therapies (orlistat, bupropion/naltrexone and liraglutide) [8] at the time of writing

This comprehensive guide will help you understand the differences, benefits, and potential of these groundbreaking treatments